Risankizumab is Superior to Ustekinumab for Induction and Maintenance of Crohn’s disease: The SEQUENCE Trial

Philip Schoenfeld, MD, MSEd, MSc (Epi) and Bharati Kochar, MD, MS discuss “Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease,” by Peyrin-Biroulet L, Chapman JC, Colombel JF, et al. N Engl J Med 2024;391:213-223.

Om Podcasten

A new monthly publication from the American College of Gastroenterology, Evidence-Based GI (EBGI) uses evidence-based methods to create abstracts and explain study results of new and important articles in the field of gastroenterology and hepatology. Listen as editors of EBGI discuss the articles they review and how the recommendations can be applied to your practice.